Rosetta Genomics, an early stage developer of microRNA-based diagnostic and therapeutic products, priced today at $7, below its anticipated range of $7.50 to $8.50. The company sold all 3.75 million shares in the offering. The underwriters were CE Unterberg Towbin and Oppenheimer. The stock is expected to begin trading tomorrow under the ticker "ROSG."
